Noxilizer Inc. 01.27.16
Noxilizer Inc. has added to its management team. The company has hired David A. Theil as its new senior vice president and chief financial officer (CFO).
Theil specializes in private equity funded startups and middle-market companies in the life sciences industry and brings more than 25 years of experience in financial, administrative and operational management, according to the company. Most recently, he worked as an interim and contract CFO in the medical device and clinical diagnostic arenas. Previous industry employment appointments include Supernus Pharmaceuticals, Specialty Pharmaceuticals; Psychiatric Genomics, Biotechnology R&D Drug Discovery; and IGEN International, Instrumentation and Diagnostics.
"David brings experience that is critical to Noxilizer at this stage of the company," Noxilizer President/CEO Lawrence Bruder said. "He has worked in growing companies and understands the opportunities and challenges."
Theil also worked at Deloitte & Touche, as manager of the Emerging Business Markets Group, where he served clients in biotechnology, communications, healthcare, and other middle-market technology companies. Theil obtained his BSc in accounting from the Kelley School of Business at Indiana University (Bloomington), and he holds a Delaware CPA certificate.
Based in Baltimore, Md., Noxilizer provides room temperature nitrogen dioxide sterilization technology that offers various benefits over traditional sterilization methods. The company sells sterilization and biodecontamination equipment to pharmaceutical, biotech and medical device manufacturers, and also offers contract sterilization services. Noxilizer is privately held and operates offices in the United States, United Kingdom and Japan.
Theil specializes in private equity funded startups and middle-market companies in the life sciences industry and brings more than 25 years of experience in financial, administrative and operational management, according to the company. Most recently, he worked as an interim and contract CFO in the medical device and clinical diagnostic arenas. Previous industry employment appointments include Supernus Pharmaceuticals, Specialty Pharmaceuticals; Psychiatric Genomics, Biotechnology R&D Drug Discovery; and IGEN International, Instrumentation and Diagnostics.
"David brings experience that is critical to Noxilizer at this stage of the company," Noxilizer President/CEO Lawrence Bruder said. "He has worked in growing companies and understands the opportunities and challenges."
Theil also worked at Deloitte & Touche, as manager of the Emerging Business Markets Group, where he served clients in biotechnology, communications, healthcare, and other middle-market technology companies. Theil obtained his BSc in accounting from the Kelley School of Business at Indiana University (Bloomington), and he holds a Delaware CPA certificate.
Based in Baltimore, Md., Noxilizer provides room temperature nitrogen dioxide sterilization technology that offers various benefits over traditional sterilization methods. The company sells sterilization and biodecontamination equipment to pharmaceutical, biotech and medical device manufacturers, and also offers contract sterilization services. Noxilizer is privately held and operates offices in the United States, United Kingdom and Japan.